|1.||Sonpavde, Guru: 8 articles (12/2015 - 01/2011)|
|2.||Petrylak, Daniel P: 6 articles (12/2015 - 06/2011)|
|3.||Shen, Liji: 6 articles (08/2015 - 10/2010)|
|4.||Sartor, Oliver: 6 articles (08/2015 - 01/2010)|
|5.||Di Lorenzo, Giuseppe: 6 articles (02/2015 - 07/2012)|
|6.||Buonerba, Carlo: 5 articles (02/2015 - 07/2012)|
|7.||de Bono, Johann S: 4 articles (12/2015 - 06/2011)|
|8.||Beuzeboc, Philippe: 4 articles (08/2015 - 04/2011)|
|9.||Vrignaud, Patricia: 4 articles (01/2015 - 06/2013)|
|10.||Pezaro, Carmel J: 4 articles (09/2014 - 02/2012)|
|1.||Prostatic Neoplasms (Prostate Cancer)
03/01/2014 - "Cabazitaxel represents a new treatment option for patients with prostate cancer. "
12/01/2010 - "Improved survival in second-line advanced prostate cancer treated with cabazitaxel."
08/01/2015 - "In vitro, cabazitaxel decreased cell viability in both enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells within the same range of concentrations. "
06/01/2015 - "Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer."
03/01/2015 - "However, whether CIP2A could increase chemoresistance of prostate cancer (PCa) cells to chemotherapeutic agent cabazitaxel remains unclear. "
10/01/2015 - "Here we report the final safety profile and anti-tumor activity of cabazitaxel in a larger population, including all patients enrolled in the expansion cohort of the study. "
03/15/2015 - "However, tumor response of both agents, particularly cabazitaxel, was lower when administered as higher-line therapy in the selected study population."
03/01/2015 - "A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors."
06/01/2014 - "An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors."
10/01/2010 - "In preclinical studies cabazitaxel inhibited cell growth in a wide range of human cancer cell lines, including tumor models expressing Pgp. "
|3.||Neoplasm Metastasis (Metastasis)
06/16/2014 - "These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases. "
10/05/2015 - "In summary, ABCB1 limits cabazitaxel brain accumulation and therefore potentially therapeutic efficacy against (micro)metastases or primary tumors positioned wholly or partly behind a functional blood-brain barrier. "
02/01/2015 - "At the time of cabazitaxel initiation, the patient had only osseous metastases and was constrained to a wheelchair because of bone pain. "
06/16/2014 - "Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports."
09/01/2014 - "Today, the picture is vastly different: several additional therapies have each demonstrated a survival benefit such that we now have chemotherapy (cabazitaxel), androgen suppressive agents (abiraterone acetate and enzalutamide), a cellular vaccine (sipuleucel-T) and radium-233 (for symptomatic bone metastases). "
|4.||Breast Neoplasms (Breast Cancer)
08/01/2012 - "Cabazitaxel has also shown activity in breast cancer and other malignancies. "
03/01/2013 - "Cabazitaxel CL was related to body surface area (BSA) and tumor type (breast cancer; finding confounded by study). "
03/01/2013 - "This analysis suggests consistent cabazitaxel PK and exposure across most solid tumor types, although the potential influence of breast cancer on CL requires further confirmation."
12/15/2012 - "Other early studies investigated the efficacy of cabazitaxel in pretreated metastatic breast cancer, either as a single agent or in combination with capecitabine. "
01/01/2015 - "We also developed cabazitaxel-resistant variants from MCF-7 breast cancer cells by stepwise selection in drug alone (MCF-7/CTAX) or drug plus the transport inhibitor PSC-833 (MCF-7/CTAX-P). "
05/01/2014 - "We report interim safety results from an Italian prospective, single-arm, multicenter, open-label trial of 218 patients receiving cabazitaxel 25 mg/m2 every 3 weeks plus prednisolone 10 mg/day, until disease progression, unacceptable toxicity, investigator's decision or death. "
09/01/2015 - "More recently, cabazitaxel (C), a novel taxane chemotherapy, has been found to prolong survival in patients who exhibit disease progression during or after D chemotherapy. "
04/01/2014 - "Enrolled patients with progressive mCRPC received cabazitaxel (25 mg/m2) plus 10mg oral prednisone/prednisolone every 3 weeks until disease progression, death, unacceptable toxicity or physician/patient decision. "
05/15/2013 - "Abiraterone acetate and cabazitaxel are approved by FDA as second-line treatments for patients with CRPC who experience disease progression during first-line docetaxel therapy. "
09/01/2011 - "Upon disease progression after first-line docetaxel chemotherapy, cabazitaxel and abiraterone improve survival of patients with CRPC and are important novel treatment options. "
|2.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)